Mylan Wins PTAB Review Of Diabetes Drug In Rare Rehearing
In a rare ruling, the Patent Trial and Appeal Board on Monday reconsidered an earlier decision and instituted an American Invents Act review of a patent on AstraZeneca AB's diabetes drugs...To view the full article, register now.
Already a subscriber? Click here to view full article